Ag85B + ESAT-6 + kallikrein + ODN1a

This is an experimental multi-component vaccine candidate composed of four elements: - Ag85B (Antigen 85B): a major secreted protein from Mycobacterium tuberculosis involved in cell wall synthesis and a strong immunogen. - ESAT-6 (Early Secreted Antigenic Target 6 kDa): another immunodominant antigen from M. tuberculosis, known for inducing robust T-cell responses and used in TB diagnostics and vaccine research. - Kallikrein: likely refers to a serine protease family member, sometimes used as an adjuvant or immune modulator; its specific role here is not well-documented in the context of TB vaccines. - ODN1a (Oligodeoxynucleotide 1a): typically denotes a synthetic CpG oligonucleotide acting as a Toll-like receptor 9 agonist to enhance immune responses. The combination aims to induce strong Th1-type cellular immunity against M. tuberculosis by leveraging the synergistic effects of Ag85B and ESAT-6 antigens, with kallikrein potentially enhancing antigen processing or presentation, and ODN1a serving as an immunostimulatory adjuvant. This formulation has not been described in published clinical trials or preclinical studies as a single entity but is conceptually similar to subunit vaccines combining mycobacterial antigens with potent adjuvants[1][3][5]. The primary indication would be prevention of tuberculosis.

Other names

Ag85B-ESAT-6-kallikrein-ODN1aAg-85B-ESAT-6-kallikrein-ODN1aAg 85B-ESAT-6-kallikrein-ODN1aAg85B/ESAT-6/kallikrein/ODN1a